MRNA injection aims to turn back the clock on aging
Disease control
Not yet recruiting
This early-stage trial tests an mRNA drug called aKL003 that instructs cells to produce alpha klotho, a protein linked to longevity. About 21 healthy adults aged 50-90 will receive two injections four weeks apart. The main goal is to check safety and whether the protein levels ri…
Phase: PHASE1 • Sponsor: Klothea Bio Inc • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC